Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy
Sign Up to like & getrecommendations! Published in 2022 at "Brain and Behavior"
DOI: 10.1002/brb3.2555
Abstract: To report side effect frequency and severity in patients with major depressive disorder (MDD) receiving escitalopram and aripiprazole adjunctive therapy and to examine whether pretreatment anxious depression is associated with the number and presence of… read more here.
Keywords: effect frequency; frequency severity; side effect; side ... See more keywords
The combination of escitalopram and aripiprazole: Investigation of psychomotor effects in rats
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Psychopharmacology"
DOI: 10.1177/0269881117732515
Abstract: Pre-clinical and clinical evidence suggests that the antidepressant efficacy of the selective serotonin reuptake inhibitor escitalopram can be enhanced by the dopamine and serotonin partial agonist aripiprazole. Given the range of possible neurochemical interactions between… read more here.
Keywords: psychomotor effects; escitalopram aripiprazole; escitalopram; psychomotor ... See more keywords
Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Psychiatry"
DOI: 10.3389/fpsyt.2022.830301
Abstract: Objective Ketamine, an N-methyl D-aspartate (NMDA) receptor antagonist, can promote rapid action in the management of individuals with treatment-resistant depression (TRD) at sub-anesthetic doses. However, few studies have investigated the long-term use of ketamine administered… read more here.
Keywords: maintenance; ketamine; depression; trial ... See more keywords